Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape

Progressive pulmonary fibrosis (PPF) describes a phenotype of non-idiopathic pulmonary fibrosis (IPF) interstitial lung diseases (ILDs) that continues to worsen despite appropriate management, leading to lung scarring, loss of lung function, and early mortality.

Current antifibrotic agents slow the rate of forced vital capacity (FVC) decline but do not halt or reverse fibrosis, leaving substantial unmet needs in survival, symptom control, and quality of life. Against this backdrop, the late-stage pipeline consists of both inhaled and targeted therapies that are expected to transform PPF care, according to GlobalData, an lintelligence and productivity platform.